Table 3. Summary of treatments, response, and adverse events.
| Dose* (mg/kg) | Concomitant treatment** | Administration period (days) | cRECIST response (days) | Clinical response (days) | Classification of discontinuation | Adverse events (grade) | |
|---|---|---|---|---|---|---|---|
| 1 | 1.64 | - | 14 | NA | Progress | TP | - |
| 2 | 0.74 | - | 21 | PD | - | AE | Anorexia (2) |
| 3 | 1.37 | CBDCA (20) | 544 | PD | - | TP | ScP (1), CoP (1), anorexia ROL (2) |
| 4 | 1.02 | CBDCA (5) | 141 | SD (56) | - | AE | Diarrhea (1), ScP (1), SkP (1), increased t-Bil (1) |
| 5 | 1.18 | - | 207 | PR (147) | - | AE | ScP (2), CoP (1), anorexia ROL (2) |
| 6 | 1.11 | - | 74 | PD | - | TP | - |
| 7 | 1.05 | - | 60 | PD | - | TP | - |
| 8 | 1.43 | CBDCA (1) | 52 | PD | - | TP | - |
| 9 | 0.96 | - | 249 | NA | Response (49)*** | TP | ScP (1), SkP (2) |
| 10 | 0.97 | - | 322< | PD | ScP (1) | ||
| 11 | 1.00 | - | 182< | NA | Response (120) | ScP (2), CoP (2), SkP (1) |
*Tegafur/gimeracil/oteracil was administered twice-daily (BID) on alternate days, Monday-Wednesday-Friday (M-W-F) weekly, **The number in parentheses shows the administration number of CBDCA, *** seizure controlled for 49 days (n=1). AE: adverse event, CoP: corneal pigmentation, CBDCA: carboplatin, NA: not assessed, cRECIST: canine response evaluation criteria in solid tumors, PD: progressive disease, PR: partial response, ROL: related to olfactory loss, ScP: scleral pigmentation, SD: stable disease, SkP: skin pigmentation, TP: tumor progression.